Moderate

Local anaesthetic agents — selection & maximum safe doses

Pharmacology · Perioperative & Anaesthesia
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Rational choice of local anaesthetic by onset, duration, toxicity profile and site, with strict adherence to weight-based maximum doses to prevent local anaesthetic systemic toxicity. Absorption varies by injection site, and additives such as adrenaline modify duration and safe dose.

Red flags

  • Perioral numbness, tinnitus, metallic taste, agitation or drowsiness during/after injection
  • Seizures or cardiovascular collapse (LAST)
  • Cyanosis unresponsive to oxygen after prilocaine (methaemoglobinaemia)
  • Total dose approaching or exceeding the weight-based maximum

Assessment

Differential diagnosis

  • Appropriate dose within safe limits
  • Impending/actual LAST from dose or site exceeding safe absorption
  • Inadvertent intravascular injection
  • Methaemoglobinaemia (prilocaine/benzocaine)
  • Allergy (true ester allergy rare; amide allergy very rare)

Investigations

  • Weight-based maximum dose calculation before injection
  • Continuous ECG, SpO2 and conscious-level monitoring during significant local anaesthetic administration
  • Methaemoglobin level (co-oximetry) if cyanosis unresponsive to oxygen after prilocaine/benzocaine
  • Assessment of injection site vascularity (intercostal/mucosal absorb fastest)

Management

  • Select the agent by need: lidocaine for rapid onset/short duration; bupivacaine/levobupivacaine/ropivacaine for prolonged blocks
  • Calculate the patient's maximum safe dose in mg by weight and convert to volume for the chosen concentration
  • Account for site of injection (highly vascular sites give higher peak levels) and reduce dose accordingly
  • Use adrenaline-containing solutions to prolong effect and reduce peak plasma levels where appropriate (avoid in end-arterial sites)
  • Aspirate before and during injection and inject incrementally, watching for early toxicity
  • Ensure monitoring and lipid emulsion are immediately available for any significant dose
  • Recognise LAST early (perioral tingling, tinnitus, agitation, seizures, arrhythmia) and treat per protocol
  • Document agent, concentration, total dose and any additives

Drugs & doses

Lidocaine — maximum 3 mg/kg plain, 7 mg/kg with adrenaline
Bupivacaine/Levobupivacaine — maximum 2 mg/kg (do NOT use for intravenous regional anaesthesia due to cardiotoxicity)
Prilocaine — maximum 6 mg/kg (preferred for intravenous regional anaesthesia; risk of methaemoglobinaemia at high dose)
Ropivacaine — maximum ~3 mg/kg; LAST rescue — Intralipid 20% 1.5 mL/kg IV bolus then 15 mL/kg/h

Disposition

Routine care when doses are within limits; LAST or significant methaemoglobinaemia requires resuscitation and monitored/critical-care observation.

Complications & pitfalls

  • Local anaesthetic systemic toxicity (CNS then cardiovascular)
  • Methaemoglobinaemia (prilocaine/benzocaine)
  • Inadvertent intravascular injection
  • Tissue ischaemia from adrenaline in end-arterial sites

Exam pearls

  • Always calculate the maximum dose in mg/kg before you start — the commonest cause of LAST is exceeding safe dose or rapid absorption
  • Bupivacaine is markedly cardiotoxic and must never be used for intravenous regional anaesthesia; prilocaine is the agent of choice there
  • Adrenaline prolongs block and lowers peak plasma levels but is contraindicated in end-arterial regions (digits, penis)
  • Highly vascular sites (intercostal, mucosal) produce the highest plasma levels for a given dose
  • Treat methaemoglobinaemia with methylene blue 1-2 mg/kg IV if symptomatic

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.